SCHEMBL23877507

SCHEMBL23877507

O=C(NC12CC(c3ccccc3)(C1)C2)c1ccccc1NS(=O)(=O)c1ccc(I)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KCNA5 P22460 5/20 0.43
▸ KDM4E B2RXH2 4/20 0.43
▸ ALDH1A1 P00352 4/20 0.43
▸ NPC1 O15118 1/20 0.42
▸ RAB9A P51151 1/20 0.42
▸ ITGA1 P56199 1/20 0.42
▸ KMT2A Q03164 3/20 0.41
▸ MEN1 O00255 2/20 0.41
▸ POLB P06746 1/20 0.41
▸ HTT P42858 2/20 0.41
▸ LMNA P02545 1/20 0.41
▸ CYP3A4 P08684 1/20 0.41
▸ CYP2D6 P10635 1/20 0.41
▸ CYP2C9 P11712 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ CRHBP P24387 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ CRHR2 Q13324 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ NOD2 Q9HC29 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30547601 0.89 KCNA5 (0.46) KCNA5KDM4EALDH1A1NPC1RAB9A
SCHEMBL23877574 0.80 ALDH1A1 (0.42) KCNA5KDM4EALDH1A1KMT2AMEN1
SCHEMBL31046915 0.80 ALDH1A1 (0.42) KCNA5KDM4EALDH1A1KMT2AMEN1
SCHEMBL23877597 0.77 KCNA5 (0.53) KCNA5HTTLMNA
SCHEMBL23877434 0.77 AVPR2 (0.42) KCNA5KDM4EALDH1A1KMT2AMEN1
SCHEMBL23879580 0.76 ALDH1A1 (0.68) KDM4EALDH1A1ITGA1KMT2AMEN1
SCHEMBL23877636 0.76 GPR27 (0.42) KCNA5KDM4EALDH1A1KMT2AMEN1
SCHEMBL23877605 0.76 USP2 (0.49) KCNA5ALDH1A1KMT2AMEN1HTT
SCHEMBL23877456 0.76 HSD17B2 (0.42) USP36
SCHEMBL23877572 0.75 USP2 (0.49) KCNA5KMT2AMEN1USP36GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12606522-B2 Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives ORSOBIO, INC. (US) 2026-04-21 — — US disclosed
US-20240409508-A1 SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES ORSOBIO, INC. 2024-12-12 — — US disclosed
US-12049439-B2 Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives ORSOBIO, INC. (US) 2024-07-30 — — US disclosed
EP-3796975-B1 SULFONYLAMINOBENZAMIDE DERIVATIVES ORSOBIO INC (US) 2023-08-30 — — EP disclosed
EP-3796975-B1 SULFONYLAMINOBENZAMIDE DERIVATIVES ORSOBIO INC (US) 2023-08-30 — — EP disclosed
US-20220055985-A1 SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES GILEAD SCIENCES, INC. 2022-02-24 — — US disclosed
US-20220055985-A1 SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES GILEAD SCIENCES, INC. 2022-02-24 — — US disclosed
US-11136290-B2 Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives THE LIVER COMPANY INC. (US) 2021-10-05 — — US disclosed
US-11136290-B2 Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives THE LIVER COMPANY INC. (US) 2021-10-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220055985-A1 SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES STS, SULT2A1, SCN2B KCNA5 264/4885KDM4E 3158/4885ALDH1A1 245/4885
US-12049439-B2 Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives STS, SULT2A1, SCN2B KCNA5 264/4885KDM4E 3158/4885ALDH1A1 245/4885
US-12606522-B2 Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives NR3C2, NR5A1, SRD5A2 KCNA5 1285/4885KDM4E 3921/4885ALDH1A1 1507/4885
US-20240409508-A1 SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES STS, SULT2A1, SCN2B KCNA5 264/4885KDM4E 3158/4885ALDH1A1 245/4885
US-11136290-B2 Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives STS, SULT2A1, SCN2B KCNA5 264/4885KDM4E 3158/4885ALDH1A1 245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback